GlassScriptPhysician profile
Mindy S Johnson
NPI 1316206337
$6,639.15
in general payments reported to CMS, 2019-2025
28 companies · $1,934 in 2025
The $1,934 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.66 · 2022: $363 · 2023: $2,308 · 2024: $2,018 · 2025: $1,934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,199 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,198.85 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,277.27 | 2022-2025 | |
| Novo Nordisk INC | $1,237.17 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $716.58 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $575.12 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $550.94 | 2022-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $446.04 | 2022-2025 | Xifaxan |
| Abbott Laboratories | $244.80 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $234.11 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Exact Sciences Corporation | $224.39 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.24 | 2023-2025 | Jardiance, Ofev |
| Abbvie INC. | $150.85 | 2023-2025 | |
| Amgen INC. | $116.67 | 2023-2025 | Repatha, Otezla, Otezla |
| Sumitomo Pharma America, INC. | $92.99 | 2023-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $83.67 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $71.19 | 2022-2024 | Belsomra, Capvaxive, Steglatro |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $64.01 | 2023 | Xarelto |
| Inspire Medical Systems, INC. | $54.08 | 2023-2024 | Inspire |
| Sanofi-Aventis U.S. LLC | $37.58 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.26 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.85 | 2022 | |
| Philips North America LLC | $34.94 | 2023 | |
| Dynavax Technologies Corporation | $31.14 | 2025 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $29.44 | 2019-2022 | |
| Cequr Corporation | $19.49 | 2025 | Cequr Simplicity |
| Amneal Pharmaceuticals LLC | $16.59 | 2023 | Unithroid |
| Alexion Pharmaceuticals, INC. | $16.24 | 2025 | Strensiq |
| Ibsa Pharma INC. | $14.23 | 2025 | Flector, Licart, Tirosint |
| Phathom Pharmaceuticals, INC. | $12.27 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mindy Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.